The merger effectively strengthens both halves of the company. It provides Sienna (formally) with new targets and potential products and it gives BD-1 a research base and expertise in commercialization. A further advantage for BD-1 is that they are not restricted to products based on Bard-1 (which it appears is all they were concerned with previously). The sky’s now the limit with potential new areas of interest and products. Combining platforms will also possibly improve BD-1s diagnostic approach. Time will tell I suppose but I feel that this is a strong move with great potential. I do wonder if there will be a name change in the future given that it’s now not all about just BARD-1.
Chart, page-627
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
58.0¢ |
Change
0.015(2.65%) |
Mkt cap ! $63.96M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 58.0¢ | 56.0¢ | $38.51K | 68.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2293 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 58.0¢ | 13111 | 1 |
View Market Depth
| Last trade - 15.48pm 12/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |